| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |